We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 39

Viropharma to acquire Swedish pharma in deal worth up to $164.6 million
  • Shook Hardy & Bacon LLP
  • USA
  • November 3 2011

Pennsylvania-based ViroPharma Inc. has reportedly signed a deal to acquire Swedish company DuoCort Pharma AB to expand its orphan disease commercial product pipeline


Quebec establishes new venture capital fund to invest in biotech research
  • Shook Hardy & Bacon LLP
  • Canada
  • February 24 2011

Quebec's Charest administration has reportedly launched the third of three new venture capital funds to provide more than $41 million for investment in biotechnology research


Agilent Technologies acquires BIOCIUS Life Sciences
  • Shook Hardy & Bacon LLP
  • USA
  • March 10 2011

California-based Agilent Technologies has announced the acquisition of BIOCIUS Life Sciences, a Massachusetts-based company that developed a spectrometry device, enabling "researchers to gain a fuller understanding of a drug's biochemical properties, including potential liabilities in drug interactions


Corporate venture funding for funding surges
  • Shook Hardy & Bacon LLP
  • USA
  • August 7 2014

Silicon Valley Bank (SVB) has issued a report that explores health-care and biotech investments and exits based on 2013 data and concludes, "Large


Royalty financing gains favor for VC biotech funding
  • Shook Hardy & Bacon LLP
  • USA
  • August 29 2013

According to a former venture capitalist (VC), a recent deal involving a royalty in exchange for a cash infusion to develop and commercialize a


Biotech companies struggling in public markets
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

While five venture-capital backed biotech companies have reportedly gone public in 2011, each has been forced to lower its offering price even before the initial public offering took place due to weakened demand


NASDAQ Biotechnology Index surpasses all-time high in 1Q13
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe


Biotech raises $30 million to develop rare muscle disease treatments
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

San Francisco-based Audentes Therapeutics Inc. has closed a $30-million Series A financing round led by OrbiMed Advisors and including 5AM Ventures


Molecular diagnostics company nets $27.7 million from common stock offering
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Illinois-based Nanosphere, Inc. has reportedly closed a public offering of more than 17 million shares of common stock at $1.75 per share, including


Biotech IPO boom continues
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

According to Xconomy's National Biotech Editor Luke Timmerman, the 24 biotech initial public offerings (IPOs) in 2013 are double those normally seen